Tagworks Pharmaceuticals is a clinical-stage precision oncology company using its proprietary Click-to-Release linker platform to develop a new standard of care for patients suffering from solid tumors.

Tagworks is developing a pipeline of novel cancer treatments leveraging its proprietary Click-to-Release technology in a range of therapeutics modalities, including antibody-drug conjugates (ADCs) and targeted radiopharmaceutical therapies. Its lead programs include, TGW101, an ADC targeting TAG-72, a non-internalizing marker found on the surface of many solid tumor cells and TGW211, a radioimmunoconjugate targeting HER2-positive cancers. The Company is headquartered in the Netherlands with operations in the U.S.

More information: www.tagworkspharma.com/company